Edwards Reports Superior TAVR Results Compared To Clinical Surveillance In At-Risk Feature
Nov 2 (Reuters) - Edwards Lifesciences Corporation EW.N:
PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
EDWARDS LIFESCIENCES CORPORATION - TAVR DELIVERS OVER 30% REDUCTION IN DEATH OR HEART FAILURE EVENTS VERSUS CLINICAL SURVEILLANCE
EDWARDS LIFESCIENCES CORPORATION - TAVR SHOWS NO MORTALITY AND NO DISABLING STROKES AT 30 DAYS
EDWARDS LIFESCIENCES CORPORATION - TAVR REDUCES HEART FAILURE HOSPITALIZATIONS BY OVER 50% AND IMPROVES QUALITY OF LIFE
EDWARDS LIFESCIENCES CORPORATION - TAVR SHOWS 33% RELATIVE REDUCTION IN DEATH OR HEART FAILURE EVENTS AT TWO YEARS
EDWARDS LIFESCIENCES CORPORATION - TAVR PATIENTS SHOW 15.5-POINT IMPROVEMENT IN QUALITY OF LIFE AT 30 DAYS
Further company coverage: EW.N